Strong traction in all the segments and an increase in price led to the growth of the top line | Piramal Pharma Q2 FY23 Result & Earning Call Highlights
Strong traction in all the segments and an increase in price led to the growth of the top line | Piramal Pharma Q2 FY23 Result & Earning Call Highlights
Strong traction in all the segments and an increase in price led to the growth of the top line | Piramal Pharma Q2 FY23 Result & Earning Call Highlights
Published on 17 November 2022 .Views 11.Comments 0